Heinz A Horst
Overview
Explore the profile of Heinz A Horst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1777
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kantarjian H, Zugmaier G, Bruggemann M, Wood B, Horst H, Zeng Y, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830762
Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph-)...
2.
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik V, Paschka P, Kronke J, et al.
Blood
. 2020 Dec;
136(26):3041-3050.
PMID: 33367545
Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials....
3.
Schlenk R, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
J Clin Oncol
. 2019 Dec;
38(6):623-632.
PMID: 31851556
Purpose: High CD33 expression in acute myeloid leukemia (AML) with mutated provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial...
4.
Rucker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
Blood
. 2019 Sep;
134(19):1608-1618.
PMID: 31554635
We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1+ AML, using a qRT-PC-based assay with...
5.
Lengfelder E, Gorlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, et al.
Eur J Haematol
. 2017 Nov;
100(2):154-162.
PMID: 29114972
Objectives: Randomized comparison of two treatment strategies in frontline therapy of acute promyelocytic leukemia (APL): all-trans retinoic acid (ATRA) and double induction intensified by high-dose cytosine arabinoside (HD ara-C) (German...
6.
Gokbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, et al.
Haematologica
. 2017 Jan;
102(4):e132-e135.
PMID: 28082340
No abstract available.
7.
Hutter-Kronke M, Benner A, Dohner K, Krauter J, Weber D, Moessner M, et al.
Haematologica
. 2016 Apr;
101(7):839-45.
PMID: 27036160
Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic...
8.
Topp M, Gokbuget N, Stein A, Zugmaier G, OBrien S, Bargou R, et al.
Lancet Oncol
. 2014 Dec;
16(1):57-66.
PMID: 25524800
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19, an antigen consistently expressed on B-lineage...
9.
Schlenk R, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al.
Blood
. 2014 Oct;
124(23):3441-9.
PMID: 25270908
The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard...
10.
Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, et al.
Ann Hematol
. 2012 Oct;
92(1):41-52.
PMID: 23090499
Despite improvement of prognosis, older age remains a negative prognostic factor in acute promyelocytic leukemia (APL). Reports on disease characteristics and outcome of older patients are conflicting. We therefore analyzed...